![](https://financialmodelingprep.com/image-stock/REVBW.png)
Revelation Biosciences, Inc. (REVBW)
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
$1.59M
Mr. James M. Rolke
New York, NY
-
0.00
$-4.77
3.40
3.45
272.77%
0.00%
0.37
0.33
0.00
3.40
63.26%
164.24%
Similar stocks (2)
Inspirato Incorporated
ISPOW
Revelation Biosciences, Inc.
REVB
Similar stocks (2)
Inspirato Incorporated
ISPOW
Revelation Biosciences, Inc.
REVB